Clinical Comparative Evaluation of Maprotiline, a New Antidepressant Drug

Publisher Website
Google Scholar
Abstract
A multicentre trial involving six psychiatric centres was set up in order to evaluate the antidepressant activity of a new compound, maprotiline (Ludiomil®), compared to that of imipramine and amitriptyline. The investigation was carried out according to a double-blind between-patient design; the Hamilton rating scale for depression was used as the main basis for assessment. 135 hospitalized patients entered the trial, 104 presenting endogenous depression and 31 neurotic depression. The results showed that maprotiline is an effective and welltolerated antidepressant drug, its overall activity being quantitatively of the same order as that observed with the reference drugs. The new drug acts particularly favourably in neurotic depression.

This publication has 1 reference indexed in Scilit: